The ColonSentry test requires only a small blood sample and can thus be easily incorporated as a pre-screening measure into routine yearly physical exams.
The assay measures the level of expression of seven genes, which can reflect the current presence or severity of a disease state, using RNA contained in blood
Interpretation of the status of these seven genes, acting as biomarkers, can allow physicians to identify patients who have an increased current risk of having colorectal cancer.
Enzo plans shipment of the product in March 2012.
Enzo Biochem president Barry Weiner said the information provided by ColonSentry test can guide their recommendation for a colonoscopy.